MiNK Therapeutics
INKT
25 hedge funds and large institutions have $1.71M invested in MiNK Therapeutics in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 0 closing their positions.
39% more funds holding
Funds holding: 18 → 25 (+7)
34% more capital invested
Capital invested by funds: $1.28M → $1.71M (+$429K)
1.24% more ownership
Funds ownership: 2.02% → 3.26% (+1.2%)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$443K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
+$332K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$50.4K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$18.6K |
| 5 |
Citigroup
New York
|
+$4.35K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$54.2K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$8.15K |
| 3 |
BlackRock
New York
|
-$1.23K |
| 4 |
Morgan Stanley
New York
|
-$142 |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$90 |
INKT Hedge Fund Activity: Q4 2025 in Review
25 of the 8,275 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q4 2025, worth a combined $1.71M — up 34% from $1.28M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new INKT positions and 0 closed out — a net gain of 7 holders — while 3 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $443K. The largest seller was Renaissance Technologies, cutting an estimated $54.2K.
- 25 institutional investors held MiNK Therapeutics (INKT) as of Q4 2025, up from 18 in Q3 2025.
- Funds reported $1.71M of MiNK Therapeutics stock for Q4 2025, up 34% quarter-over-quarter.
- 7 funds opened new MiNK Therapeutics positions in Q4 2025 and 0 closed out, a net change of +7 holders.
- The largest MiNK Therapeutics buyer in Q4 2025 was Vanguard Group, an estimated $443K added.
- The largest MiNK Therapeutics seller in Q4 2025 was Renaissance Technologies, an estimated $54.2K sold.
Based on aggregated 13F filings for Q4 2025.